Endocrinology Search

Endocrinology

Endocrinology

Home News Diseases Conferences Special Reports Multimedia

hypophosphatemia%20-and-%20hyperphosphatemia

HYPOPHOSPHATEMIA & HYPERPHOSPHATEMIA

Hypophosphatemia is an electrolyte imbalance where there is a decrease in the serum phosphate level that is less than the normal range.

It is recognized most often in critically-ill patients, decompensated diabetics, alcoholics or other malnourished persons, and acute infectious or pulmonary disorders.

It may be transient and reflect intracellular shift with minimal clinical consequences.

Hyperphosphatemia is an electrolyte disturbance in which an increase in the serum phosphate level of more than the normal range is present.

Most symptoms of acute hyperphosphatemia are due to secondary hypocalcemia.

The significant level of hyperphosphatemia in adults is >6 mg/dL.

Hypophosphatemia%20-and-%20hyperphosphatemia Management

Management

Monitoring

Monitoring of Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients

Monitoring of serum phosphate in CKD patients should start in patients with grade 3 CKD
- Frequency of monitoring will be based on the presence and magnitude of abnormalities and the rate of progression of the disease
Monitoring of serum phosphate intervals may be as followed:
- Every 6-12 months in patients with grade 3 CKD
- Every 3-6 months in patients with grade 4 CKD
- Every 1-3 months in patients with grade 5 CKD

Migraine a risk factor for dementia?

Pearl Toh, 6 days ago

Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.

Daily alcohol intake, certain drugs tied to liver abnormalities in PsA patients

5 days ago

Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.

Pembrolizumab + chemo improves PFS in previously untreated, advanced TNBC

Christina Lau, 4 days ago

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.